ADRONALINE
ActiveSummary
The annual accounts of ADRONALINE for financial year 2025 show a net loss of 174% of total assets and of 91% of the equity at the start of that year. The 2025 annual accounts show equity of €953 and a net result of -€9,906. Equity is shrinking by about 37% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 20% of 10,771 sector peers (NACE 70, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
23-11
Gazette deed
Appointment: LERAY Véronique, Marc, Anne (statutory director)Power of attorney · Registered office clause · Amendment of the articles8 facts ▸
- Director appointment, LERAY Véronique, Marc, Anne (statutory director)
- Power of attorney, Florence Debouche
- Registered office clause, “1340 Ottignies-Louvain-la-Neuve,rue des Erables,5, actionnaire unique en lieu et place de l’assemblée générale” (deed in French)
- Power of attorney
- General meeting, 20-11-2023
- Other provision, “lien matrimonial déclaré, épouse” (deed in French)
- Amendment of the articles (2 times)
- Capital conversion, “actionnaire unique,en lieu et place de l'assemblée générale, de plein droit” (deed in French)
27-12
Gazette deed
Resignations & appointmentsDirector in office2 facts ▸
- General meeting, 06-12-2022
- Director in office, Véronique Leray (director)
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 2 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.